TY - JOUR
T1 - Survival of Patients with Hepatocellular Carcinoma (HCC)Treated by Percutaneous Radio-Frequency Ablation(RFA) Is Affected by Complete Radiological Response
AU - Di Marco, Vito
AU - Cabibbo, Giuseppe
AU - Butera, Giuseppe
AU - Brancatelli, Giuseppe
AU - Raineri, Santi Maurizio
AU - Camma', Calogero
AU - Giarratano, Antonino
AU - Midiri, Massimo
AU - Craxi, Antonio
AU - Galia, Massimo
AU - Genco, Chiara
AU - Maida, Marcello Fabio
PY - 2013
Y1 - 2013
N2 - Background: Radio-frequency ablation (RFA) has been employed in the treatment of Barcelona Clinic Liver Cancer (BCLC)early stage hepatocellular carcinoma (HCC) as curative treatments.Aim: To assess the effectiveness and the safety of RFA in patients with early HCC and compensated cirrhosis.Methods: A cohort of 151 consecutive patients with early stage HCC (122 Child-Pugh class A and 29 class B patients) treatedwith RFA were enrolled. Clinical, laboratory and radiological follow-up data were collected from the time of first RFA. Asingle lesion was observed in 113/151 (74.8%), two lesions in 32/151 (21.2%), and three lesions in 6/151 (4%) of patients.Results: The overall survival rates were 94%, 80%, 64%, 49%, and 41% at 12, 24, 36, 48 and 60 months, respectively.Complete response (CR) at 1 month (p,0.0001) and serum albumin levels (p = 0.0004) were the only variablesindipendently linked to survival by multivariate Cox model. By multivariate analysis, tumor size (p = 0.01) is the only variableassociated with an increased likehood of CR. The proportion of major complications after treatment was 4%.Conclusions: RFA is safe and effective for managing HCC with cirrhosis, especially for patients with HCC #3 cm and higherbaseline albumin levels. Complete response after RFA significantly increases survival.
AB - Background: Radio-frequency ablation (RFA) has been employed in the treatment of Barcelona Clinic Liver Cancer (BCLC)early stage hepatocellular carcinoma (HCC) as curative treatments.Aim: To assess the effectiveness and the safety of RFA in patients with early HCC and compensated cirrhosis.Methods: A cohort of 151 consecutive patients with early stage HCC (122 Child-Pugh class A and 29 class B patients) treatedwith RFA were enrolled. Clinical, laboratory and radiological follow-up data were collected from the time of first RFA. Asingle lesion was observed in 113/151 (74.8%), two lesions in 32/151 (21.2%), and three lesions in 6/151 (4%) of patients.Results: The overall survival rates were 94%, 80%, 64%, 49%, and 41% at 12, 24, 36, 48 and 60 months, respectively.Complete response (CR) at 1 month (p,0.0001) and serum albumin levels (p = 0.0004) were the only variablesindipendently linked to survival by multivariate Cox model. By multivariate analysis, tumor size (p = 0.01) is the only variableassociated with an increased likehood of CR. The proportion of major complications after treatment was 4%.Conclusions: RFA is safe and effective for managing HCC with cirrhosis, especially for patients with HCC #3 cm and higherbaseline albumin levels. Complete response after RFA significantly increases survival.
UR - http://hdl.handle.net/10447/82083
M3 - Book/Film/Article review
VL - 8
JO - PLoS One
JF - PLoS One
SN - 1932-6203
ER -